SCHEMBL1119003

SCHEMBL1119003

c1ccc2c(c1)-c1ccccc1C2CN1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 2/20 0.49
HRH3 Q9Y5N1 3/20 0.48
ABCB1 P08183 4/20 0.47
LMNA P02545 1/20 0.46
HTR2A P28223 1/20 0.45
TSHR P16473 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN3A Q9NY46 1/20 0.42
CHRNA7 P36544 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29575598 1.00 METAP1 (0.49) METAP1HRH3ABCB1LMNAHTR2A
SCHEMBL28397007 0.98 HTR2A (0.47) METAP1HRH3ABCB1LMNAHTR2A
SCHEMBL15688648 0.81 SIGMAR1 (0.46) HRH3LMNAHTR2ATSHR
SCHEMBL295894 0.81 L3MBTL1 (0.49) LMNAHTR2ATSHR
SCHEMBL8819866 0.80 ABCB1 (0.55) ABCB1LMNATSHRADRA2AADRA2B
SCHEMBL21995339 0.80 ACHE (0.52) HRH3LMNAHTR2A
SCHEMBL8820497 0.78 ABCB1 (0.53) ABCB1LMNAHTR2AADRA2AADRA2B
SCHEMBL2050300 0.77 TSHR (0.39) METAP1HRH3HTR2ATSHRCHRNA7
SCHEMBL2052235 0.77 TSHR (0.39) METAP1HRH3HTR2ATSHRCHRNA7
SCHEMBL3816899 0.76 HTR2A (0.42) HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4079737-B1 SYSTEM AND METHOD FOR SOLUTION PHASE GAP PEPTIDE SYNTHESIS UNIV TEXAS TECH SYSTEM (US) 2026-02-11 EP disclosed
EP-4644406-A1 RADIOLABELED MEDICINE National University Corporation Chiba University (JP) 2025-11-05 EP disclosed
US-12344632-B2 System and method for solution phase gap peptide synthesis TEXAS TECH UNIVERSITY SYSTEM (US) 2025-07-01 US disclosed
US-20240391949-A1 COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS SEDERMA (FR) 2024-11-28 US disclosed
WO-2024150477-A1 METHOD FOR PRODUCING AMINO GROUP-CONTAINING COMPOUND, METHOD FOR SEPARATING AMINO GROUP-CONTAINING COMPOUND, AND APPARATUS FOR PRODUCING AMINO GROUP-CONTAINING COMPOUND 株式会社トクヤマ 2024-07-18 WO disclosed
EP-3689892-B1 RADIOACTIVE DRUG UNIV CHIBA NAT UNIV CORP (JP) 2024-07-17 EP disclosed
US-12030888-B2 Himastatin derivatives, and processes of preparation thereof, and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-07-09 US disclosed
WO-2024143314-A1 RADIOLABELED MEDICINE 国立大学法人千葉大学 2024-07-04 WO disclosed
US-20240217995-A1 COMPOSITIONS FOR CHEMICAL SYNTHESIS OF PEPTIDES SEDERMA (FR) 2024-07-04 US disclosed
US-12024537-B2 Compositions and methods for chemical synthesis SEDERMA (FR) 2024-07-02 US disclosed
EP-0292729-B1 PROCESS FOR SOLID PHASE PEPTIDE SYNTHESIS BACHEM AG (CH) 1992-04-22 EP disclosed
US-5101059-A Xanthene compounds RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1992-03-31 US disclosed
WO-1991008190-A1 AMINO ACID PROTECTING GROUPS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1991-06-13 WO disclosed
EP-0394194-A1 Protected amino-acids and process for their preparation CALBIOCHEM-NOVABIOCHEM AG (CH) 1990-10-24 EP disclosed
US-4923901-A Membranes with bound oligonucleotides and peptides MILLIPORE CORPORATION (US) 1990-05-08 US disclosed
US-4914151-A Resin-linker combination for the solid-phase synthesis of peptides and intermediates BACHEM FEINCHEMIKALEIN A.G. (CH) 1990-04-03 US disclosed
US-4831084-A Resin-linker combination for the solid-phase synthesis of peptides and intermediates BACHEM FEINCHEMIKALIEN A.G. (CH) 1989-05-16 US disclosed
EP-0305929-A2 Membranes with bound oligonucleotides and peptides MILLIPORE CORPORATION (US) 1989-03-08 EP disclosed
EP-0292729-A2 Process for solid phase peptide synthesis BACHEM AG (CH) 1988-11-30 EP disclosed
US-4108846-A FOR PRODUCTION OF POLYPEPTIDES HOFFMANN-LA ROCHE INC. 1978-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030888-B2 Himastatin derivatives, and processes of preparation thereof, and uses thereof PCSK9, HMGCR, PCSK7 METAP1 288/4885HRH3 1373/4885ABCB1 339/4885
US-12344632-B2 System and method for solution phase gap peptide synthesis SBDS, NGLY1, GAP43 METAP1 320/4885HRH3 3530/4885ABCB1 4056/4885
US-20240391949-A1 COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS NGLY1, DNPEP, HM13 METAP1 278/4885HRH3 3659/4885ABCB1 4802/4885
US-12024537-B2 Compositions and methods for chemical synthesis NGLY1, DNPEP, HM13 METAP1 278/4885HRH3 3659/4885ABCB1 4802/4885
US-20240217995-A1 COMPOSITIONS FOR CHEMICAL SYNTHESIS OF PEPTIDES PTMS, DNPEP, ANPEP METAP1 42/4885HRH3 3498/4885ABCB1 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.